A small difference in the molecular structure of angiotensin II receptor blockers induces AT1 receptor-dependent and -independent beneficial effects

被引:45
作者
Fujino, Masahiro
Miura, Shin-ichiro [1 ,2 ]
Kiya, Yoshihiro
Tominaga, Yukio [3 ]
Matsuo, Yoshino
Karnik, Sadashiva S. [2 ]
Saku, Keijiro
机构
[1] Fukuoka Univ, Sch Med, Dept Cardiol, Jonan Ku, Fukuoka 8140180, Japan
[2] Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol, Cleveland, OH USA
[3] Dainippon Sumitomo Pharma Co Ltd, Genom Sci Labs, Osaka, Japan
关键词
angiotensin II type 1 receptor blocker; molecular structure; inverse agonism; insurmountability; monocyte chemoattractant protein-1; MONOCYTE CHEMOATTRACTANT PROTEIN-1; INVERSE AGONIST ACTIVITY; FACTOR-KAPPA-B; TYPE-1; RECEPTOR; CANDESARTAN; ACTIVATION; LOSARTAN; GAMMA; HYPERTENSION; ANTAGONISTS;
D O I
10.1038/hr.2010.135
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Angiotensin II (Ang II) type 1 (AT(1)) receptor blockers (ARBs) induce multiple pharmacological beneficial effects, but not all ARBs have the same effects and the molecular mechanisms underlying their actions are not certain. In this study, irbesartan and losartan were examined because of their different molecular structures (irbesartan has a cyclopentyl group whereas losartan has a chloride group). We analyzed the binding affinity and production of inositol phosphate (IP), monocyte chemoattractant protein-1 (MCP-1) and adiponectin. Compared with losartan, irbesartan showed a significantly higher binding affinity and slower dissociation rate from the AT(1) receptor and a significantly higher degree of inverse agonism and insurmountability toward IP production. These effects of irbesartan were not seen with the AT(1)-Y113A mutant receptor. On the basis of the molecular modeling of the ARBs-AT(1) receptor complex and a mutagenesis study, the phenyl group at Tyr(113) in the AT(1) receptor and the cyclopentyl group of irbesartan may form a hydrophobic interaction that is stronger than the losartan-AT(1) receptor interaction. Interestingly, irbesartan inhibited MCP-1 production more strongly than losartan. This effect was mediated by the inhibition of nuclear factor-kappa B activation that was independent of the AT(1) receptor in the human coronary endothelial cells. In addition, irbesartan, but not losartan, induced significant adiponectin production that was mediated by peroxisome proliferator-activated receptor-gamma activation in 3T3-L1 adipocytes, and this effect was not mediated by the AT(1) receptor. In conclusion, irbesartan induced greater beneficial effects than losartan due to small differences between their molecular structures, and these differential effects were both dependent on and independent of the AT(1) receptor. Hypertension Research (2010) 33, 1044-1052; doi:10.1038/hr.2010.135; published online 29 July 2010
引用
收藏
页码:1044 / 1052
页数:9
相关论文
共 37 条
[1]   Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity [J].
Benson, SC ;
Pershadsingh, HA ;
Ho, CI ;
Chittiboyina, A ;
Desai, P ;
Pravenec, M ;
Qi, NN ;
Wang, JM ;
Avery, MA ;
Kurtz, TW .
HYPERTENSION, 2004, 43 (05) :993-1002
[2]   PPAR γ-activating angiotensin type-1 receptor blockers induce adiponectin [J].
Clasen, R ;
Schupp, M ;
Foryst-Ludwig, A ;
Sprang, C ;
Clemenz, M ;
Krikov, M ;
Thöne-Reineke, C ;
Unger, T ;
Kintscher, U .
HYPERTENSION, 2005, 46 (01) :137-143
[3]  
Engelhardt S, 2001, MOL PHARMACOL, V60, P712
[4]   Angiotensin IV activates the nuclear transcription factor-κB and related proinflammatory genes in vascular smooth muscle cells [J].
Esteban, V ;
Ruperez, M ;
Sánchez-López, E ;
Rodríguez-Vita, J ;
Lorenzo, O ;
Demaegdt, H ;
Vanderheyden, P ;
Egido, J ;
Ruiz-Ortega, MR .
CIRCULATION RESEARCH, 2005, 96 (09) :965-973
[5]   Mechanism of constitutive activation of the AT1 receptor:: Influence of the size of the agonist switch binding residue Asn111 [J].
Feng, YH ;
Miura, SI ;
Husain, A ;
Karnik, SS .
BIOCHEMISTRY, 1998, 37 (45) :15791-15798
[6]   Modeling of loops in protein structures [J].
Fiser, A ;
Do, RKG ;
Sali, A .
PROTEIN SCIENCE, 2000, 9 (09) :1753-1773
[7]  
Herrick-Davis K, 2000, J PHARMACOL EXP THER, V295, P226
[8]   Anti-inflammatory and metabolic effects of candesartan in hypertensive patients [J].
Koh, KK ;
Quon, MJ ;
Han, SH ;
Chung, WJ ;
Lee, Y ;
Shin, EK .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2006, 108 (01) :96-100
[9]   Comparison of effects of Losartan, Irbesartan, and Candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension [J].
Koh, KK ;
Han, SH ;
Chung, WJ ;
Ahn, JY ;
Jin, DK ;
Kim, HS ;
Park, GS ;
Kang, WC ;
Ahn, TH ;
Shin, EK .
AMERICAN JOURNAL OF CARDIOLOGY, 2004, 93 (11) :1432-1435
[10]   Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan -: Role of the active metabolite EXP3179 [J].
Krämer, C ;
Sunkomat, J ;
Witte, J ;
Luchtefeld, M ;
Walden, M ;
Schmidt, B ;
Böger, RH ;
Forssmann, WG ;
Drexler, H ;
Schieffer, B .
CIRCULATION RESEARCH, 2002, 90 (07) :770-776